Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155216644975
Abstract: Rasburicase is a recombinant urate oxidase enzyme administered for treatment of hyperuricemia associated with tumor lysis syndrome. Studies demonstrate effectiveness of single fixed-dose rasburicase as compared to the FDA-approved dose of 0.2 mg/kg intravenously daily for… read more here.
Keywords: uric acid; single fixed; rasburicase; dose rasburicase ... See more keywords